



Biorelevant dissolution behavior of amorphous furosemide forms as determined by UV imaging and Raman spectroscopy.

Gordon, Sarah; Nielsen, Line Hagner; Pajander, Jari Pekka; Østergaard, Jesper; Rades, Thomas; Müllertz, Anette

Publication date:
2014

Document Version
Early version, also known as pre-print

[Link back to DTU Orbit](#)

Citation (APA):

Gordon, S., Nielsen, L. H., Pajander, J. P., Østergaard, J., Rades, T., & Müllertz, A. (2014). *Biorelevant dissolution behavior of amorphous furosemide forms as determined by UV imaging and Raman spectroscopy.* Poster session presented at 2013 AAPS Annual Meeting and Exposition, San Antonio, Texas, United States.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Biorelevant dissolution behavior of amorphous furosemide forms as determined by UV imaging and Raman spectroscopy

Sarah Gordon¹, [Line Hagner Nielsen](#)², Jari Pekka Pajander², Jesper Østergaard², Thomas Rades², Anette Müllertz^{2,3}

¹Department of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarland University, Saarbrücken, Germany

²Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

³Bioneer:FARMA, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

PURPOSE: To investigate the biorelevant dissolution behavior of amorphous furosemide sodium salt and an amorphous furosemide acid form, and obtain information regarding the solid state of these amorphous forms during dissolution.

METHODS: Amorphous furosemide sodium salt and an acid form of amorphous furosemide were prepared by spray drying. Their dissolution behavior was evaluated in a biorelevant intestinal medium at pH 6.5. Dissolution was investigated using a flow-through cell coupled to a UV imaging system, and further quantified by UV spectrophotometric analysis of flow cell effluent samples. The solid state form of amorphous furosemide compacts during dissolution was also investigated using *in situ* Raman spectroscopy, as well as off-line X-ray powder diffraction (XRPD). Furthermore, thermogravimetric analysis (TGA) and hot stage microscopy were utilized for investigation of the polymorphic form of remaining amorphous salt upon dissolution.

RESULTS: UV imaging and analysis of effluent samples showed that the amorphous furosemide salt exhibited a greater dissolution rate than the amorphous acid form, as well as crystalline acid and salt forms of furosemide. Both amorphous furosemide forms were shown to convert extremely quickly (within 1 min) to more stable crystalline forms during dissolution. Partial least squares-discriminant analysis modeling of the Raman spectroscopic data obtained during the biorelevant dissolution showed that the amorphous acid form converted to the crystalline acid form of furosemide within 20 min. This was also confirmed by XRPD of amorphous acid compacts following dissolution. TGA and hot stage microscopy investigations showed that the amorphous salt converted to a trihydrate of furosemide during biorelevant dissolution. Principal component analysis of the Raman spectral data recorded during the dissolution process indicated that this conversion started at the time of drug wetting.

CONCLUSIONS: Evaluation of the biorelevant dissolution behavior of amorphous furosemide salt and acid forms indicated a dissolution advantage of the amorphous salt form, but also showed that a rapid solid state conversion to a more stable polymorph occurred in the case of both amorphous furosemide salt and acid. Such behavior could significantly influence the *in vivo* performance of amorphous furosemide, and demonstrates the importance of biorelevant *in vitro* drug characterization.